Pyxis Oncology (NASDAQ:PYXS) Issues Earnings Results

Pyxis Oncology (NASDAQ:PYXS) posted its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.

Pyxis Oncology Stock Down 3.0%

NASDAQ:PYXS traded down $0.05 during mid-day trading on Thursday, reaching $1.61. The stock had a trading volume of 1,149,574 shares, compared to its average volume of 834,470. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The stock’s 50 day simple moving average is $2.54 and its two-hundred day simple moving average is $2.16.

Wall Street Analyst Weigh In

Several research firms have weighed in on PYXS. HC Wainwright upped their target price on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Wells Fargo & Company boosted their price target on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pyxis Oncology in a research note on Friday, September 25th. Stifel Nicolaus set a $5.00 price objective on Pyxis Oncology in a report on Thursday. Finally, Wedbush boosted their target price on Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.57.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.